CN101220370B - 双歧杆菌-大肠杆菌穿梭表达载体及其制备方法和用途 - Google Patents
双歧杆菌-大肠杆菌穿梭表达载体及其制备方法和用途 Download PDFInfo
- Publication number
- CN101220370B CN101220370B CN 200810300178 CN200810300178A CN101220370B CN 101220370 B CN101220370 B CN 101220370B CN 200810300178 CN200810300178 CN 200810300178 CN 200810300178 A CN200810300178 A CN 200810300178A CN 101220370 B CN101220370 B CN 101220370B
- Authority
- CN
- China
- Prior art keywords
- expression vector
- coli shuttle
- bifidobacteria
- bacillus
- shuttle expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000013604 expression vector Substances 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 239000013612 plasmid Substances 0.000 claims abstract description 50
- 241000894006 Bacteria Species 0.000 claims abstract description 27
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 24
- 108090000637 alpha-Amylases Proteins 0.000 claims abstract description 12
- 102100034014 Prolyl 3-hydroxylase 3 Human genes 0.000 claims abstract description 6
- 101710150114 Protein rep Proteins 0.000 claims abstract description 6
- 101710152114 Replication protein Proteins 0.000 claims abstract description 6
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 58
- 230000000968 intestinal effect Effects 0.000 claims description 16
- 241000588724 Escherichia coli Species 0.000 claims description 13
- 229940126578 oral vaccine Drugs 0.000 claims description 13
- 239000012634 fragment Substances 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 238000012216 screening Methods 0.000 claims description 7
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 claims description 4
- 230000000688 enterotoxigenic effect Effects 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 230000014509 gene expression Effects 0.000 abstract description 28
- 239000013598 vector Substances 0.000 abstract description 11
- 238000004519 manufacturing process Methods 0.000 abstract description 8
- 241000186000 Bifidobacterium Species 0.000 abstract description 4
- 238000010353 genetic engineering Methods 0.000 abstract 2
- 241001608472 Bifidobacterium longum Species 0.000 abstract 1
- 229940009291 bifidobacterium longum Drugs 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 230000010473 stable expression Effects 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 18
- 108091008146 restriction endonucleases Proteins 0.000 description 17
- 102100026894 Lymphotoxin-beta Human genes 0.000 description 13
- 229960005486 vaccine Drugs 0.000 description 12
- 239000000047 product Substances 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 101150018411 LTB gene Proteins 0.000 description 8
- 230000010076 replication Effects 0.000 description 8
- 238000001962 electrophoresis Methods 0.000 description 7
- 238000003304 gavage Methods 0.000 description 7
- 239000013605 shuttle vector Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000012408 PCR amplification Methods 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 3
- 241000588722 Escherichia Species 0.000 description 3
- 108020005091 Replication Origin Proteins 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- XQCZBXHVTFVIFE-UHFFFAOYSA-N 2-amino-4-hydroxypyrimidine Chemical compound NC1=NC=CC(O)=N1 XQCZBXHVTFVIFE-UHFFFAOYSA-N 0.000 description 2
- 239000004382 Amylase Substances 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- 108010080611 Cytosine Deaminase Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 235000019418 amylase Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- QENJLXATANVWMR-UHFFFAOYSA-N 2-[(3-amino-3-imino-2-methylpropanethioyl)amino]acetic acid Chemical compound NC(=N)C(C)C(=S)NCC(O)=O QENJLXATANVWMR-UHFFFAOYSA-N 0.000 description 1
- 241000186013 Bifidobacterium asteroides Species 0.000 description 1
- 241000186156 Bifidobacterium indicum Species 0.000 description 1
- 241000186160 Bifidobacterium pseudolongum subsp. globosum Species 0.000 description 1
- 241000459479 Capsula Species 0.000 description 1
- 102000000311 Cytosine Deaminase Human genes 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101500026378 Homo sapiens Endostatin Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 101150049281 PRM1 gene Proteins 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 101001003495 Pseudomonas fluorescens Lipase Proteins 0.000 description 1
- 101001064559 Pseudomonas fluorescens Lipase Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241001655322 Streptomycetales Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 101150099105 alien gene Proteins 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200810300178 CN101220370B (zh) | 2008-01-22 | 2008-01-22 | 双歧杆菌-大肠杆菌穿梭表达载体及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200810300178 CN101220370B (zh) | 2008-01-22 | 2008-01-22 | 双歧杆菌-大肠杆菌穿梭表达载体及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101220370A CN101220370A (zh) | 2008-07-16 |
CN101220370B true CN101220370B (zh) | 2013-02-27 |
Family
ID=39630446
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200810300178 Active CN101220370B (zh) | 2008-01-22 | 2008-01-22 | 双歧杆菌-大肠杆菌穿梭表达载体及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101220370B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109575107B (zh) * | 2018-11-26 | 2022-03-08 | 上海华新生物高技术有限公司 | 一种细胞穿透肽及可表达口服干扰素的双歧杆菌 |
CN116144690A (zh) * | 2022-08-23 | 2023-05-23 | 江西省科学院微生物研究所(江西省流域生态研究所) | 一种大肠杆菌与乳酸菌的穿梭载体pDXA及构建方法与应用 |
-
2008
- 2008-01-22 CN CN 200810300178 patent/CN101220370B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN101220370A (zh) | 2008-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102622910B1 (ko) | Pd-1 호밍 엔도뉴클레아제 변이체, 조성물 및 사용 방법 | |
KR102604096B1 (ko) | 윌슨병을 치료하기 위한 유전자 치료 | |
KR102683284B1 (ko) | 세균 감염의 치료를 위한 살세균제와 라이소좀향성 알칼리화제와의 조합물 | |
US20250135031A1 (en) | Single-vector gene construct comprising insulin and glucokinase genes | |
AU774643B2 (en) | Compositions and methods for use in recombinational cloning of nucleic acids | |
DK2768848T3 (en) | METHODS AND PROCEDURES FOR EXPRESSION AND SECRETARY OF PEPTIDES AND PROTEINS | |
KR20170108946A (ko) | Fc 수용체-유사 5를 표적화하는 키메라 항원 수용체 및 그의 용도 | |
CN112041334A (zh) | 人foxp3在经基因编辑的t细胞中的表达 | |
CN112725282A (zh) | 携带正交tRNA/氨酰tRNA合成酶的稳定细胞系的构建 | |
CN114990157B (zh) | 用于构建lmna基因突变的扩张型心肌病模型猪核移植供体细胞的基因编辑系统及其应用 | |
CN107849579B (zh) | 用于基因优化的方法 | |
CN114507664B (zh) | 合成启动子及其构建方法和应用 | |
CN101220370B (zh) | 双歧杆菌-大肠杆菌穿梭表达载体及其制备方法和用途 | |
CN109295100A (zh) | 携带正交tRNA/氨酰tRNA合成酶的稳定细胞系的构建 | |
PT91520A (pt) | Processo para a preparacao de proteinas por expressao de proteinas homologas e heterologas funcionais a partir da membrana exterior de e. coli e de outras bacterias gram-negativas | |
CN112342234B (zh) | 一种调控n-乙酰神经氨酸产量提高的重组枯草芽孢杆菌 | |
CN113817759B (zh) | 修饰的因子ix、组合物、方法及其在基因治疗中的应用 | |
RU2781083C2 (ru) | Варианты, композиции и методы применения хоминг-эндонуклеазы pd-1 | |
CN116323924B (zh) | 基因疗法载体、包含载体的重组逆转录病毒和用于预防或治疗癌症的药物组合物 | |
CN112538104B (zh) | 构建促融质粒优化禽腺病毒Fiber-2蛋白表达及纯化的方法 | |
KR102712198B1 (ko) | 재조합 발생이 최소화된 유전자치료 벡터, 상기 벡터를 포함하는 재조합 레트로바이러스 및 상기 재조합 레트로바이러스를 포함하는 암의 예방 또는 치료용 약학 조성물 | |
Puah | Selective binding to mRNA duplex regions by chemically modified PNAs stimulates ribosomal frameshifting | |
KR102083729B1 (ko) | 에스트로겐성 화합물의 검출능을 갖는 아데닐레이트 사이클레이스 기반의 박테리아 균주 및 이를 이용한 에스트로겐성 화합물의 검출 방법 | |
CN115247186A (zh) | 一种构建af双基因突变的动脉粥样硬化模型猪核移植供体细胞的基因编辑系统及其应用 | |
HK40024481A (zh) | Wiskott-aldrich綜合征和x連鎖血小板減少症中的治療性基因組編輯 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190530 Address after: Room 601 and 613, Building 1, Jinzhuang No.1 Hospital, Haidian District, Beijing Patentee after: Beijing Ande thinking General Trading Co., Ltd. Address before: 400016 Medical University Of Chongqing, Yuzhong 1 medical college, Medical University Of Chongqing Patentee before: Chongqing Medical University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201201 Address after: Room 606, unit 2, No. 106, Lianhuachi East Road, Xicheng District, Beijing 100045 Patentee after: Beijing aishikai Health Management Development Co., Ltd Address before: Room 601 and 613, Building 1, Jinzhuang No.1 Hospital, Haidian District, Beijing Patentee before: BEIJING ANDESIKAOPU TRADE Co.,Ltd. |
|
TR01 | Transfer of patent right |